391 related articles for article (PubMed ID: 28008867)
1. Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect?
Cattaneo D; Minisci D; Cozzi V; Riva A; Meraviglia P; Clementi E; Galli M; Gervasoni C
Antivir Ther; 2017; 22(4):353-356. PubMed ID: 28008867
[TBL] [Abstract][Full Text] [Related]
2. Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study.
Orrell C; Hagins DP; Belonosova E; Porteiro N; Walmsley S; Falcó V; Man CY; Aylott A; Buchanan AM; Wynne B; Vavro C; Aboud M; Smith KY;
Lancet HIV; 2017 Dec; 4(12):e536-e546. PubMed ID: 28729158
[TBL] [Abstract][Full Text] [Related]
3. Dolutegravir in HIV-2-Infected Patients With Resistant Virus to First-line Integrase Inhibitors From the French Named Patient Program.
Descamps D; Peytavin G; Visseaux B; Tubiana R; Damond F; Campa P; Charpentier C; Khuong-Josses MA; Duvivier C; Karmochkine M; Lukiana T; Matheron S
Clin Infect Dis; 2015 May; 60(10):1521-7. PubMed ID: 25690598
[TBL] [Abstract][Full Text] [Related]
4. Drug-Drug Interaction between the Direct-Acting Antiviral Regimen of Ombitasvir-Paritaprevir-Ritonavir plus Dasabuvir and the HIV Antiretroviral Agent Dolutegravir or Abacavir plus Lamivudine.
Khatri A; Trinh R; Zhao W; Podsadecki T; Menon R
Antimicrob Agents Chemother; 2016 Oct; 60(10):6244-51. PubMed ID: 27503645
[TBL] [Abstract][Full Text] [Related]
5. Dolutegravir for the treatment of adult patients with HIV-1 infection.
Wu G; Abraham T; Saad N
Expert Rev Anti Infect Ther; 2014 May; 12(5):535-44. PubMed ID: 24694091
[TBL] [Abstract][Full Text] [Related]
6. Bioequivalence of a dolutegravir, abacavir, and lamivudine fixed-dose combination tablet and the effect of food.
Weller S; Chen S; Borland J; Savina P; Wynne B; Piscitelli SC
J Acquir Immune Defic Syndr; 2014 Aug; 66(4):393-8. PubMed ID: 24798770
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies.
Llibre JM; Hung CC; Brinson C; Castelli F; Girard PM; Kahl LP; Blair EA; Angelis K; Wynne B; Vandermeulen K; Underwood M; Smith K; Gartland M; Aboud M
Lancet; 2018 Mar; 391(10123):839-849. PubMed ID: 29310899
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging people living with HIV.
Courlet P; Stader F; Guidi M; Alves Saldanha S; Stoeckle M; Cavassini M; Battegay M; Buclin T; Decosterd LA; Marzolini C;
AIDS; 2020 Jan; 34(1):103-108. PubMed ID: 31490233
[TBL] [Abstract][Full Text] [Related]
9. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.
Raffi F; Jaeger H; Quiros-Roldan E; Albrecht H; Belonosova E; Gatell JM; Baril JG; Domingo P; Brennan C; Almond S; Min S;
Lancet Infect Dis; 2013 Nov; 13(11):927-35. PubMed ID: 24074642
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacokinetics and pharmacodynamics of dolutegravir used as a single tablet regimen for the treatment of HIV-1 infection.
Bollen P; Reiss P; Schapiro J; Burger D
Expert Opin Drug Saf; 2015; 14(9):1457-72. PubMed ID: 26134478
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice.
Borghetti A; Lombardi F; Gagliardini R; Baldin G; Ciccullo A; Moschese D; Emiliozzi A; Belmonti S; Lamonica S; Montagnani F; Visconti E; De Luca A; Di Giambenedetto S
BMC Infect Dis; 2019 Jan; 19(1):59. PubMed ID: 30654739
[TBL] [Abstract][Full Text] [Related]
12. Intentional overdose of dolutegravir/abacavir/lamivudine (Triumeq) in a 26-year-old man.
van Dam PM; van Geffen MW; Havenith TR; Posthouwer D
Antivir Ther; 2018; 23(6):549-552. PubMed ID: 29533918
[TBL] [Abstract][Full Text] [Related]
13. Dolutegravir/lamivudine (Dovato)--a two-drug complete regimen for HIV-1 infection.
Med Lett Drugs Ther; 2019 Aug; 61(1579):134-136. PubMed ID: 31581158
[No Abstract] [Full Text] [Related]
14. The effect of veno-arterial extracorporeal oxygenation and nasogastric tube administration on the pharmacokinetic profile of abacavir, lamivudine and dolutegravir: a case report.
Blackman AL; Heil EL; Devanathan AS; Pandit NS
Antivir Ther; 2020; 25(2):115-119. PubMed ID: 32341207
[TBL] [Abstract][Full Text] [Related]
15. [Position of dolutegravir in the treatment of HIV infection].
Martínez E; Gatell JM
Enferm Infecc Microbiol Clin; 2015 Mar; 33 Suppl 1():31-3. PubMed ID: 25858610
[TBL] [Abstract][Full Text] [Related]
16. Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study.
Molina JM; Clotet B; van Lunzen J; Lazzarin A; Cavassini M; Henry K; Kulagin V; Givens N; de Oliveira CF; Brennan C;
Lancet HIV; 2015 Apr; 2(4):e127-36. PubMed ID: 26424673
[TBL] [Abstract][Full Text] [Related]
17. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study.
Clotet B; Feinberg J; van Lunzen J; Khuong-Josses MA; Antinori A; Dumitru I; Pokrovskiy V; Fehr J; Ortiz R; Saag M; Harris J; Brennan C; Fujiwara T; Min S;
Lancet; 2014 Jun; 383(9936):2222-31. PubMed ID: 24698485
[TBL] [Abstract][Full Text] [Related]
18. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study.
Raffi F; Rachlis A; Stellbrink HJ; Hardy WD; Torti C; Orkin C; Bloch M; Podzamczer D; Pokrovsky V; Pulido F; Almond S; Margolis D; Brennan C; Min S;
Lancet; 2013 Mar; 381(9868):735-43. PubMed ID: 23306000
[TBL] [Abstract][Full Text] [Related]
19. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial.
van Lunzen J; Maggiolo F; Arribas JR; Rakhmanova A; Yeni P; Young B; Rockstroh JK; Almond S; Song I; Brothers C; Min S
Lancet Infect Dis; 2012 Feb; 12(2):111-8. PubMed ID: 22018760
[TBL] [Abstract][Full Text] [Related]
20. Dolutegravir-based monotherapy or dual therapy maintains a high proportion of viral suppression even in highly experienced HIV-1-infected patients.
Gubavu C; Prazuck T; Niang M; Buret J; Mille C; Guinard J; Avettand-Fènoël V; Hocqueloux L
J Antimicrob Chemother; 2016 Apr; 71(4):1046-50. PubMed ID: 26712907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
